Dr. Essam Sheta, Director of Biochemistry of Power3 Medical Products, Named to American Institute of Biological Sciences' Parkinson's Review Panel.

HOUSTON -- Dr. Essam Sheta, Director of Biochemistry of Power3 Medical Products, Inc., a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases, has been named to the American Institute of Biological Sciences (AIBS) to be on its review panel for grant proposals related to Parkinson's disease.

The AIBS has been tasked by the U.S. Army Medical Research and Materiel Command (USAMRMC) Neurotoxin Exposure and Treatment Research Program (NETRP) to convene a peer review panel to review novel and innovative research proposals related to Parkinson's disease. The USAMRMC is soliciting research proposals for studies on the pathophysiology, surrogate markers, mechanisms and treatment of Parkinson's disease and Parkinson's-related neurodegenerative conditions to include initiating causes, interaction of environmental and genetic risk factors, epigenetic modifying factors, with emphasis on exposure factors encountered in military operations which may be neurotoxic or lead to neurodegenerative conditions.

Dr. Sheta took part in the AIBS review panel's meetings in Reston, Virginia, earlier this month.

A key member of the scientific staff at Power3 since June 2001, Dr. Sheta has more than 28 years of broad academic and research experience in protein biochemistry and cancer cell signaling from Alexandria University in Egypt, Washington State University, The University of Texas Medical Center at San Antonio and The University of Virginia. He was awarded the prestigious Fulbright Scholarship at The University of Texas at San Antonio where he provided the first bidomain structural proof of nitric oxide synthase, the most complex human enzyme known. This was followed by his unique methodology in the first commercial production of the enzyme by overexpression in E. coli. As an Associate Professor of the Department of Biochemistry at Alexandria University, he supervised several graduate students for Master and Ph.D. degrees in biochemistry and served on the Fulbright Committee Review Board in Cairo. In 1998, he was honored with an Excellence in Science Award from Alexandria University for his distinguished research accomplishments.

At Power3 Medical, Dr. Sheta has utilized his scientific expertise and strategy skills in leading to several discoveries of many disease biomarkers. He contributed in drawing strategic plans for the developmental methods and research in proteomics, clinical trial biomarkers validation and commercialization of biomarkers, and has also played a key role in the development of multiple business relationships, and co-authoring more than 20 patents and numerous peer review journals publications as well.

"Everyone at Power3 is very proud of Dr. Sheta for the recognition given him in being named to this prestigious panel and position," said Seven B. Rash, the company's CEO. "Much of the work Dr. Sheta has done here at Power3 concerning blood-based early detection of Parkinson's and other neurodegenerative diseases will serve him well in his time on this vitally important review panel."

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. (PWRM.PK, www.power3medical.com) is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease, and its identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art proteomics laboratory in The Woodlands (Houston), Texas.

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.